Vaccitech is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells. Founded by Adrian Hill and Sarah Gilbert in 2016, Vaccitech is backed by investors that include Sequoia Capital, GV, Oxford Sciences Innovation, Future Planet Capital, and Korea Investment Partners and is headquartered in Oxford.